Skip to main navigation Skip to search Skip to main content

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: A real-world study Dr Stefano Vella

  • Fanpu Ji
  • , Wenjun Wang
  • , Shuangsuo Dang
  • , Shengbang Wang
  • , Burong Li
  • , Dan Bai
  • , Wenxue Zhao
  • , Hong Deng
  • , Changyin Tian
  • , Zongfang Li
  • Xi'an Jiaotong University

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background: Direct-acting antivirals have been used for decompensated cirrhotic patients with hepatitis C virus (HCV) infection. However, the benefits in Chinese patients with decompensated cirrhosis are unclear. Methods: Thirty patients with HCV infection and decompensated cirrhosis were administered sofosbuvir-containing regimens at our hospital between April and December 2015. The efficacy and safety of the treatments was determined by sustained virological response at week 12 (SVR 12), change of liver function and adverse events. Results: The cohort included 13 treatment-experienced and 17 treatment-naïve patients. A total of 27 patients (90%) achieved SVR 12. No baseline characteristics (sex, age, treatment-experience, genotype, viral load, liver function or splenectomy) was association with achievement of SVR 12. Patients achieved SVR 12 had significantly improved liver function by post-treatment week 12 (P < 0.05). Of the 30 patients, six developed anemia, one developed hepatic decompensation, two developed impaired renal function and one developed a severe upper respiratory tract infection during the treatment. There was no death or HCC development during 12 months of follow-up off-therapy. Two patients (7.4%) with SVR 12 experienced new decompensated episodes during the follow-up. Conclusion: Sofosbuvir-containing regimens are effective in Chinese HCV patients with decompensated cirrhosis, regardless of baseline characteristics, as demonstrated by a high rate of SVR 12, as well as improvement in liver function. Although antiviral therapy is generally well tolerated, a vigilant monitoring of anemia and renal function should be mandatory.

Original languageEnglish
Article number48
JournalInfectious Agents and Cancer
Volume12
Issue number1
DOIs
StatePublished - 13 Sep 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anemia
  • Child-Pugh score
  • Decompensated cirrhosis
  • Hepatitis C virus
  • Renal dysfunction
  • Sofosbuvir

Fingerprint

Dive into the research topics of 'Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: A real-world study Dr Stefano Vella'. Together they form a unique fingerprint.

Cite this